Literature DB >> 20603607

Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword?

Ling-Hui Zeng1, Sharon McDaniel, Nicholas R Rensing, Michael Wong.   

Abstract

Identification of cell signaling mechanisms mediating seizure-related neuronal death and epileptogenesis is important for developing more effective therapies for epilepsy. The mammalian target of rapamycin (mTOR) pathway has recently been implicated in regulating neuronal death and epileptogenesis in rodent models of epilepsy. In particular, kainate-induced status epilepticus causes abnormal activation of the mTOR pathway, and the mTOR inhibitor, rapamycin, can decrease the development of neuronal death and chronic seizures in the kainate model. Here, we discuss the significance of these findings and extend them further by identifying upstream signaling pathways through which kainate status epilepticus activates the mTOR pathway and by demonstrating limited situations where rapamycin may paradoxically increase mTOR activation and worsen neuronal death in the kainate model. Thus, the regulation of seizure-induced neuronal death and epileptogenesis by mTOR is complex and may have dual, opposing effects depending on the physiological and pathological context. Overall, these findings have important implications for designing potential neuroprotective and antiepileptogenic therapies that modulate the mTOR pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20603607      PMCID: PMC3934644          DOI: 10.4161/cc.9.12.11866

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  32 in total

1.  Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials.

Authors:  N R Temkin
Journal:  Epilepsia       Date:  2001-04       Impact factor: 5.864

2.  Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic.

Authors:  M Castedo; K F Ferri; G Kroemer
Journal:  Cell Death Differ       Date:  2002-02       Impact factor: 15.828

3.  AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling.

Authors:  Douglas R Bolster; Stephen J Crozier; Scot R Kimball; Leonard S Jefferson
Journal:  J Biol Chem       Date:  2002-05-07       Impact factor: 5.157

4.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Authors:  Ken Inoki; Yong Li; Tianquan Zhu; Jun Wu; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

5.  Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice.

Authors:  Jing Zhou; Jacqueline Blundell; Shiori Ogawa; Chang-Hyuk Kwon; Wei Zhang; Christopher Sinton; Craig M Powell; Luis F Parada
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 6.  Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

7.  The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy.

Authors:  Ling-Hui Zeng; Nicholas R Rensing; Michael Wong
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167

8.  Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E.

Authors:  Diane C Fingar; Sofie Salama; Christina Tsou; Ed Harlow; John Blenis
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

9.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.

Authors:  Brendan D Manning; Andrew R Tee; M Nicole Logsdon; John Blenis; Lewis C Cantley
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

10.  Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy.

Authors:  Paul S Buckmaster; Elizabeth A Ingram; Xiling Wen
Journal:  J Neurosci       Date:  2009-06-24       Impact factor: 6.167

View more
  17 in total

1.  The expanding relevance of nuclear mTOR in carcinogenesis.

Authors:  Jung H Back; Arianna L Kim
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

Review 2.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

3.  Rapamycin for treatment of epilepsy: antiseizure, antiepileptogenic, both, or neither?

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2011-03       Impact factor: 7.500

4.  Before epilepsy unfolds: finding the epileptogenesis switch.

Authors:  Annamaria Vezzani
Journal:  Nat Med       Date:  2012-11       Impact factor: 53.440

5.  Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.

Authors:  Bo Zhang; Michael Wong
Journal:  Epilepsia       Date:  2012-01-13       Impact factor: 5.864

6.  Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures.

Authors:  Linglin Chen; Lin Hu; Jing-Yin Dong; Qing Ye; Nan Hua; Michael Wong; Ling-Hui Zeng
Journal:  Epilepsia       Date:  2012-11       Impact factor: 5.864

7.  Proteomic Analysis After Status Epilepticus Identifies UCHL1 as Protective Against Hippocampal Injury.

Authors:  James P Reynolds; Eva M Jimenez-Mateos; Li Cao; Fang Bian; Mariana Alves; Suzanne F Miller-Delaney; An Zhou; David C Henshall
Journal:  Neurochem Res       Date:  2017-04-10       Impact factor: 3.996

8.  One hour of pilocarpine-induced status epilepticus is sufficient to develop chronic epilepsy in mice, and is associated with mossy fiber sprouting but not neuronal death.

Authors:  Ling-Lin Chen; Hang-Feng Feng; Xue-Xia Mao; Qing Ye; Ling-Hui Zeng
Journal:  Neurosci Bull       Date:  2013-03-08       Impact factor: 5.203

9.  Fetal brain mTOR signaling activation in tuberous sclerosis complex.

Authors:  Victoria Tsai; Whitney E Parker; Ksenia A Orlova; Marianna Baybis; Anthony W S Chi; Benjamin D Berg; Jacqueline F Birnbaum; Jacqueline Estevez; Kei Okochi; Harvey B Sarnat; Laura Flores-Sarnat; Eleonora Aronica; Peter B Crino
Journal:  Cereb Cortex       Date:  2012-10-18       Impact factor: 5.357

Review 10.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.